• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»market access

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

By Pallavi Madhiraju on April 28, 2026   Pharma & Biotech  

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.

Recent Posts

  • Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?
  • TytoCare just opened a new FDA category. Can AI make home ear exams clinically useful?
  • How Apotex’s generic Infuvite pediatric approval could shift the sterile injectable multivitamin market
  • Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability
  • Why BrioHealth’s Brio4Kids trial could become a test case for pediatric LVAD innovation
  • Why Humacyte, Inc.’s vascular tissue platform is gaining attention in high-risk dialysis populations
  • What ZORYVE cream’s infant indication means for non-steroidal eczema treatments
  • Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
  • Why Pacira BioSciences, Inc. is positioning EXPAREL as a cost-saving tool in Medicare surgery
  • Is direct-to-patient pharma becoming the industry’s answer to drug pricing pressure?
  • Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
  • Why the Veradermics hair loss trial is bigger than another aesthetics readout
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes